Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case--control studies

Dial, Sandra; Alrasadi, Khalid; Manoukian, Chantal; Huang, Allen; Menzies, Dick
July 2004
CMAJ: Canadian Medical Association Journal;7/6/2004, Vol. 171 Issue 1, p33
Academic Journal
Background: Antibiotic disruption of the normal intestinal flora is a well-known risk factor for Clostridium difficile-associated di-arrhea. Reduced gastric acidity has been suggested as a risk factor, and we hypothesized that proton pump inhibitors, be-cause of their potency, may be an independent risk factor for this problem. Methods: For the cohort study we identified from a pharmacy database 1187 inpatients at a Montreal teaching hospital who received antibiotics over a 9-month period beginning in Au-gust 2002. We compared patients in this group who had also received a proton pump inhibitor or an H2 blocker with pa-tients who had not received acid suppressive therapy. Hospital laboratory reports of positive assay results for C. difficile toxin were used to ascertain cases in the cohort. To assess the possibility that proton pump inhibitors were prescribed to patients who were sicker and had other risk fac-tors for C. difficile infection, we did a case--control study at a second Montreal teaching hospital. Cases were defined as pa-tients who were positive for C. difficile toxin and who had a history of diarrhea ( n = 94). Control subjects were selected from among patients who had received an antibiotic and were matched to cases by ward, age within 5 years and class of antibiotics ( n= 94). Results: In the cohort study, C. difficile diarrhea developed in 81 (6.8%) of the 1187 patients who received antibiotics while in hospital. In a multivariate analysis, C. difficile diarrhea was significantly associated with use of proton pump inhibitors (adjusted odds ratio [OR] 2.1, 95% confidence interval [CI] 1.2--3.5), receipt of 3 or more antibiotics (OR 2.1, 95% CI 1.3-- 3.4) and admission to a medical ward (OR 4.1, 95% CI 2.3-- 7.3). In the case--control study C. difficile diarrhea was associ-ated with female sex (adjusted OR 2.1, 95% CI 1.1--4.0), prior renal failure (adjusted OR 4.3, 95% CI 1.5--11.9), hospital ad-mission...


Related Articles

  • Proton pump inhibitors increase risk of Clostridium infection.  // Reactions Weekly;8/21/2004, Issue 1015, p5 

    Discusses research being done on the significance of proton pump inhibitors to Clostridium difficile diarrhoea. Reference to a study by S. Dial et al., published in the July 6, 2004 issue of the "Canadian Medical Association Journal"; Background on the use of antibacterials in the treatment of...

  • Medication Safety and Reliability. FDA: C. difficile-associated diarrhea may be associated with proton pump inhibitors.  // Formulary;Mar2012, Vol. 47 Issue 3, p105 

    The article reports on a drug safety communication which was issued in 2012 by the U.S. Food and Drug Administration. In the communication the administration indicated that the use of proton pump inhibitors may be associated with an increased risk of Clostridium difficile-associated diarrhea...

  • Clostridium difficile infection in hospitals: risk factors and responses. Louie, Thomas J.; Meddings, Jon // CMAJ: Canadian Medical Association Journal;7/6/2004, Vol. 171 Issue 1, p45 

    Discusses the risk factors of the Clostridium difficile-associated diarrhea (CDAD) in hospitals in Montréal, Quebec. Percentage of patients who use proton pump inhibitors who developed CDAD; Explanation for the increased risk of acquiring the common nosocomial pathogen; Root cause of CDAD...

  • Gastric Acid Suppression by Proton Pump Inhibitors as a Risk Factor for Clostridium Difficile-Associated Diarrhea in Hospitalized Patients. Aseeri, Mohammed; Schroeder, Todd; Kramer, Joan; Zackula, Rosalee // American Journal of Gastroenterology;Sep2008, Vol. 103 Issue 9, p2308 

    BACKGROUND: Evidence for the association between Clostridium difficile ( C. difficile) and the use of proton pump inhibitor (PPI) is unclear. This study investigated the relationship between Clostridium difficile-associated diarrhea (CDAD) and exposure to acid suppressive therapy in hospitalized...

  • Aggression of C-difficile Infections in PPI Consumers. Daniell, Harry W // American Journal of Gastroenterology;Jun2014, Vol. 109 Issue 6, p922 

    A letter to the editor in response to a research article related to the association between proton pump inhibitor (PPI) use and clostridium difficile (C-difficile) infection (CDI) recurrences published in a previous issue is presented.

  • Response to Daniell. Freedberg, Daniel E; Salmasian, Hojjat; Friedman, Carol; Abrams, Julian A // American Journal of Gastroenterology;Jun2014, Vol. 109 Issue 6, p922 

    A letter to the editor is presented in response to an article related to association between proton pump inhibitor (PPI) use and C-difficile infection (CDI) recurrences, published in a previous issue.

  • Proton pump inhibitors and the risk of Clostridium difficileassociated disease: further evidence from the community. Cunningham, Richard // CMAJ: Canadian Medical Association Journal;9/26/2006, Vol. 175 Issue 7, p757 

    The article presents a commentary on the research previously published in the "Canadian Medical Association Journal" entitled "Proton Pump Inhibitor Use and Risk of Community-Acquired Clostridium Difficile-Associated Disease Defined by Prescription for Oral Vancomycin Therapy." It discusses the...

  • Overuse of PPls blamed for soaring rates of C. difficile. Wilkinson, Emma // Pulse;7/23/2005, Vol. 65 Issue 29, p2 

    Reports that government advisers have warned GP that overprescribing of proton pump inhibitors could be contributing to spiraling outbreaks of Clostridium difficile in elderly patients in Great Britain. Move taken by the Specialist Advisory Committee on Antimicrobial Resistance (SACAR) to...

  • Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Cadle, Richard M.; Mansouri, Mohammad D.; Logan, Nancy; Kudva, Denise R.; Musher, Daniel M. // American Journal of Health-System Pharmacy;11/15/2007, Vol. 64 Issue 22, p2359 

    Purpose. The role of concurrent use of proton-pump inhibitors (PPIs) in the outcomes of treatment for Clostridium difficile colitis was studied. Methods. The records of inpatients at a large Veterans Affairs medical center in whom C. difficile colitis was diagnosed between June 2004 and July...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics